Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core-related antigen assay.

Shinya HagiwaraShigeru KusumotoTakako InoueShintaro OgawaTomoko NaritaAsahi ItoMasaki RiHirokazu KomatsuTakanori SuzukiKentaro MatsuuraShintaro YagiAtsushi KanekoKatsumi AoyagiShinsuke IidaYasuhito Tanaka

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)

iTACT-HBcrAg could be a potential surrogate marker for diagnosing early-stage HBV reactivation as well as safe cessation of NA treatment in patients with resolved HBV infection after HBV reactivation.

Keyphrases

hepatitis b virus
liver failure
early stage
squamous cell carcinoma
high throughput
risk assessment
radiation therapy
mass spectrometry
locally advanced